Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.

Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sørensen BS, Lykkesfeldt AE.

Cancer Lett. 2014 Mar 1;344(1):90-100.

PMID:
24513268
2.

Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.

Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K.

J Steroid Biochem Mol Biol. 2003 May;85(1):33-47.

PMID:
12798355
3.

Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.

Larsen SS, Egeblad M, Jäättelä M, Lykkesfeldt AE.

Breast Cancer Res Treat. 1999 Nov;58(1):41-56.

PMID:
10634517
4.

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Larsen SL, Laenkholm AV, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.

PLoS One. 2015 Feb 23;10(2):e0118346. doi: 10.1371/journal.pone.0118346. eCollection 2015.

5.

Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.

Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T.

PLoS One. 2013 Apr 4;8(4):e60889. doi: 10.1371/journal.pone.0060889. Print 2013.

6.

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, Nicholson RI, Gee JM.

Breast Cancer Res. 2011 Mar 11;13(2):R29. doi: 10.1186/bcr2848.

7.

The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.

Kirkegaard T, Yde CW, Kveiborg M, Lykkesfeldt AE.

Int J Oncol. 2014 Jul;45(1):393-400. doi: 10.3892/ijo.2014.2434. Epub 2014 May 9.

PMID:
24819550
8.

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.

Yde CW, Emdal KB, Guerra B, Lykkesfeldt AE.

Breast Cancer Res Treat. 2012 Aug;135(1):67-78. doi: 10.1007/s10549-012-2053-1. Epub 2012 Apr 18.

PMID:
22527100
9.

interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).

Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Riggins RB, Cao D, Clarke R.

Cancer Res. 2004 Jun 1;64(11):4030-9.

10.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

11.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

12.

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.

Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, van de Water B.

Breast Cancer Res. 2011 May 19;13(3):R52. doi: 10.1186/bcr2883.

13.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Lænkholm AV, Bak M, Lykkesfeldt AE, Yde CW.

Oncogene. 2015 Aug 6;34(32):4199-210. doi: 10.1038/onc.2014.351. Epub 2014 Nov 3.

PMID:
25362855
14.

Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.

Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, Mullan PB, Harkin DP.

J Natl Cancer Inst. 2007 Nov 21;99(22):1683-94. Epub 2007 Nov 13.

15.

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J, Toyooka S, Nogami T, Shien T, Doihara H, Miyoshi S.

Breast Cancer Res. 2010;12(3):R43. doi: 10.1186/bcr2598. Epub 2010 Jun 28.

16.

Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.

Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T, Christiansen IJ, Kirkegaard T, Lykkesfeldt AE.

Breast Cancer Res Treat. 2010 Jun;121(3):601-13. doi: 10.1007/s10549-009-0506-y. Epub 2009 Aug 21.

PMID:
19697122
17.

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ 2nd, de Cremoux P, Stenvang J, Lykkesfeldt AE.

Breast Cancer Res Treat. 2009 Mar;114(2):263-75. doi: 10.1007/s10549-008-0011-8. Epub 2008 Apr 14.

18.

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.

Breast Cancer Res Treat. 2010 Aug;122(3):685-97. doi: 10.1007/s10549-009-0592-x. Epub 2009 Oct 27.

PMID:
19859802
19.

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW.

Breast Cancer Res Treat. 2013 May;139(1):71-80. doi: 10.1007/s10549-013-2485-2. Epub 2013 Apr 23.

PMID:
23609470
20.

Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.

Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC.

Int J Oncol. 2007 Feb;30(2):509-20.

PMID:
17203234
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk